Related Experiment Video
Updated: Jan 30, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
Published on: August 9, 2013
Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes
Frank M Gao1,2,3, Kartik Kishore3,4, Dinesh Pandey4
1Department of Endocrinology, Austin Hospital, Melbourne, Victoria, Australia.
Aims:
To assess whether preoperative sodium-glucose co-transporter 2 inhibitor (SGLT2i) use reduces the odds of postoperative acute kidney injury (AKI) in patients with type 2 diabetes undergoing surgery.
Methods:
We conducted a target trial emulation using inverse probability of treatment weighting, utilising routinely collected data from a tertiary centre in Australia. Patients with type 2 diabetes were included. We compared patients undergoing surgery under general anaesthesia who were taking SGLT2i preoperatively with patients undergoing surgery who were not taking SGLT2i preoperatively. The primary outcome was postoperative AKI within 7 days of surgery. We estimated the average treatment effect on the treated and calculated adjusted odds ratios (ORs) and standardised risk differences.
Results:
We included 2499 patients (738 taking SGLT2i preoperatively and 1761 not taking SGLT2i preoperatively). Over half of patients underwent emergency surgery. Postoperative AKI occurred in 18.6% taking SGLT2i preoperatively and 25.8% not taking SGLT2i preoperatively. Odds of postoperative AKI were significantly lower in those who used SGLT2i preoperatively (adjusted OR 0.71, 95% CI 0.56-0.91, p = 0.007). Effects were consistent across subgroup and sensitivity analyses.
Conclusions:
In patients with type 2 diabetes who used SGLT2i preoperatively, its use reduced the odds of postoperative acute kidney injury.
Insights
Preoperative use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) significantly lowered the risk of acute kidney injury (AKI) after surgery in patients with type 2 diabetes. This finding highlights SGLT2i as a protective measure for kidney health in surgical patients.
Area of Science:
- Nephrology
- Endocrinology
- Surgical Care
Background:
- Type 2 diabetes increases surgical risk, particularly for acute kidney injury (AKI).
- Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are increasingly used for diabetes management.
- The perioperative impact of SGLT2i on AKI risk is an important clinical question.
Purpose of the Study:
- To evaluate the association between preoperative SGLT2 inhibitor use and the incidence of postoperative AKI.
- To determine if SGLT2i confers renal protection in patients with type 2 diabetes undergoing surgery.
Main Methods:
- Target trial emulation using inverse probability of treatment weighting on real-world data.
- Comparison of patients with type 2 diabetes undergoing surgery, stratified by preoperative SGLT2i use.
- Primary outcome: postoperative AKI within 7 days of surgery.
Main Results:
- 2499 patients included; 738 used preoperative SGLT2i.
- Postoperative AKI occurred in 18.6% of SGLT2i users vs. 25.8% of non-users.
- Preoperative SGLT2i use was associated with significantly lower odds of AKI (aOR 0.71, P=0.007).
Conclusions:
- Preoperative SGLT2 inhibitor use is associated with reduced odds of postoperative AKI in patients with type 2 diabetes.
- Findings suggest a potential renoprotective effect of SGLT2i in the perioperative setting.
- Results were robust across sensitivity and subgroup analyses.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Diabetes Mellitus: Type 2 and Gestational
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care

